Portfolio

Mesenkia Therapeutics, backed by UU Invest, is developing a groundbreaking treatment for glioblastoma, the most aggressive brain cancer. The startup is preparing clinical trials to create a drug aimed at extending patients’ lives.

SoundSim360, developed by Professor Ken Mattsson and Dr. Gustav Eriksson, is an advanced sound simulation tool for precise sound level predictions that handles complex acoustics, including low-frequency sounds for wind turbines, arenas, and home theater systems.

UU Invest hosts your project so that you can establish necessary agreements with collaborative partners, hire key personnel to investigate or develop the concept, and also assist ‘hands on’ in negotiations and strategic work.

Ida-Maria Sintorn, along with her colleagues in the SimSearch project, is developing new technology for image processing of microscopic images. The focus is to make it easier, faster, and safer for researchers to extract relevant information from large amounts of data while retaining control over their own data.

Oscar Verho and his research network are focused on creating more efficient ways to produce fuels from water. The path involves advanced interdisciplinary development and a sustainable, efficient electrode with the potential to make green hydrogen production more cost-effective.

PapersHive is one of UU Invest’s 55 portfolio companies. With an AI-based search technology, the company collects information from all medical databases in one place. This saves both time and money for pharmaceutical companies, CROs and medical technology companies.

Applications for VentureChallenge 2023 are now closed. A new call for applications will open again in the first quarter of 2024.

Up to 500,000 SEK for your research-based business idea. UU Invest, in collaboration with UU Innovation, is now conducting a call for start-up capital of up to 500,000 SEK for your research-based business idea.

Meet Gunilla Lundmark, CEO of UU Invest, and Malin Graffner Nordberg, Head of UU Innovation. With different roles and expertise, they work towards the same overall goal – to contribute to Uppsala University’s efforts to take research forward and utilise knowledge in society.

Ulf Landegren och hans forskningsgrupp ligger bakom banbrytande forskning som lett till nya innovationer som framgångsrikt förvaltats och utvecklats i en rad olika bolag. Rarity Bioscience med vd Linus Bosaeus är ett av de senaste i raden.